AR123188A1 - Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer - Google Patents
Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimerInfo
- Publication number
- AR123188A1 AR123188A1 ARP210102219A ARP210102219A AR123188A1 AR 123188 A1 AR123188 A1 AR 123188A1 AR P210102219 A ARP210102219 A AR P210102219A AR P210102219 A ARP210102219 A AR P210102219A AR 123188 A1 AR123188 A1 AR 123188A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide
- seq
- amino acids
- tau
- residues
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 15
- 150000001413 amino acids Chemical class 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 4
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 238000009825 accumulation Methods 0.000 abstract 2
- 230000035508 accumulation Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003982 neuronal uptake Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripción proporciona composiciones de péptidos y composiciones inmunoterapéuticas que comprenden un péptido b-amiloide (Ab, Abeta), un péptido tau y/o un péptido a-sinucleína. La descripción también proporciona métodos para tratar o efectuar la profilaxis de la enfermedad de Alzheimer u otras enfermedades con depósitos de b-amiloide en un sujeto, inclusive métodos para eliminar los depósitos, inhibir o disminuir la acumulación de Ab y/o tau y/o una sinucleína a, bloquear la absorción de las neuronas, eliminar amiloide e inhibir la propagación de las moléculas iniciales de tau y/o una sinucleinopatía por a-sinucleína en un sujeto que padezca o tenga riesgo de desarrollar la enfermedad de Alzheimer u otras enfermedades que contengan acumulaciones de tau y b-amiloide y a-sinucleína. Los métodos incluyen la administración a tales pacientes de las composiciones que comprenden un péptido amiloide b (Ab) y un péptido tau y un péptido a-sinucleína. Reivindicación 1: Un polipéptido que comprende: (a) un primer péptido que comprende de 3 a 10 aminoácidos de los residuos 1 a 10 ó 12 a 25 de la SEQ ID Nº 01; (b) un segundo péptido que comprende de 3 a 13 aminoácidos de los residuos 244 a 400 de la SEQ ID Nº 02; y (c) un tercer péptido tau que comprende de 3 a 10 aminoácidos de los residuos 81 a 140 de la SEQ ID Nº 58; donde el primer péptido, el segundo péptido y el tercer péptido están dispuestos en cualquier orden en el polipéptido. Reivindicación 38: Una composición inmunoterapéutica, que comprende: (a) una primera secuencia peptídica que comprende de 3 a 10 aminoácidos de los primeros diez o 12 a 25 residuos de extremo N de la SEQ ID Nº 01; (b) una segunda secuencia peptídica que comprende de 3 a 13 aminoácidos de los residuos 244 a 400 de la SEQ ID Nº 02; y (c) una tercera secuencia peptídica que comprende de 3 a 10 aminoácidos de los residuos 81 a 140 de la SEQ ID Nº 58.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062919P | 2020-08-07 | 2020-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123188A1 true AR123188A1 (es) | 2022-11-09 |
Family
ID=80118546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102219A AR123188A1 (es) | 2020-08-07 | 2021-08-09 | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4192497A1 (es) |
| JP (1) | JP2023536995A (es) |
| KR (1) | KR20230080397A (es) |
| CN (1) | CN116472055A (es) |
| AR (1) | AR123188A1 (es) |
| AU (1) | AU2021321549A1 (es) |
| CA (1) | CA3188456A1 (es) |
| IL (1) | IL300347A (es) |
| MX (1) | MX2023001503A (es) |
| TW (1) | TW202221017A (es) |
| WO (1) | WO2022032166A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003288035A1 (en) * | 2002-11-12 | 2004-06-03 | Riso National Laboratory | Polynucleotides encoding agmatine coumaroyltransferase (act) and uses thereof |
| GB201803387D0 (en) * | 2018-03-02 | 2018-04-18 | One Health Ventures Ltd | Disease detection |
| CN109022460B (zh) * | 2018-08-31 | 2021-05-28 | 西藏自治区农牧科学院农业研究所 | 一种bahd酰基转移酶基因及其用途 |
-
2021
- 2021-08-06 MX MX2023001503A patent/MX2023001503A/es unknown
- 2021-08-06 CA CA3188456A patent/CA3188456A1/en active Pending
- 2021-08-06 AU AU2021321549A patent/AU2021321549A1/en active Pending
- 2021-08-06 JP JP2023507949A patent/JP2023536995A/ja active Pending
- 2021-08-06 IL IL300347A patent/IL300347A/en unknown
- 2021-08-06 CN CN202180067903.XA patent/CN116472055A/zh active Pending
- 2021-08-06 EP EP21853506.0A patent/EP4192497A1/en active Pending
- 2021-08-06 KR KR1020237007790A patent/KR20230080397A/ko unknown
- 2021-08-06 WO PCT/US2021/045062 patent/WO2022032166A1/en active Application Filing
- 2021-08-09 AR ARP210102219A patent/AR123188A1/es unknown
- 2021-08-09 TW TW110129345A patent/TW202221017A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL300347A (en) | 2023-04-01 |
| JP2023536995A (ja) | 2023-08-30 |
| AU2021321549A1 (en) | 2023-03-09 |
| MX2023001503A (es) | 2023-03-08 |
| CA3188456A1 (en) | 2022-02-10 |
| CN116472055A (zh) | 2023-07-21 |
| EP4192497A1 (en) | 2023-06-14 |
| TW202221017A (zh) | 2022-06-01 |
| KR20230080397A (ko) | 2023-06-07 |
| WO2022032166A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003253A1 (es) | Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer | |
| CL2021000112A1 (es) | Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia genética y para eliminar o reducir las inmunoglobulinas | |
| Streit et al. | The role of microglia in sporadic Alzheimer’s disease | |
| CO2021012380A2 (es) | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| AR121070A1 (es) | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias | |
| KR960704839A (ko) | β-아밀로이드 단백질 생성 억제제(Inhibitors of β-amyloid protein production) | |
| DE69931793D1 (de) | Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins | |
| KR102600128B1 (ko) | 신경 질환의 치료 | |
| EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
| CA3185884A1 (en) | Pharmaceutical composition for preventing or treating a periodontal disease or dislocated traumatic tooth | |
| RU2007115411A (ru) | Пептиды hsp60 и их apl-производные и фармацевтические композиции | |
| AR123188A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| MX2023003008A (es) | Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer. | |
| MX2023003007A (es) | Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias. | |
| AR122129A1 (es) | Vacuna de tau para el tratamiento de la enfermedad de alzheimer | |
| JP2016539911A5 (es) | ||
| PE20231029A1 (es) | ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO | |
| PE20211772A1 (es) | Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados | |
| Saavedra et al. | Natural snake venom inhibitors and their pharmaceutical uses: challenges and possibilities | |
| Tsukie et al. | Decreased amount of collagen in the skin of amyotrophic lateral sclerosis in the Kii peninsula of Japan | |
| AR122126A1 (es) | Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer | |
| AR122127A1 (es) | VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER | |
| US20200289589A1 (en) | Compositions and methods for treating alzheimer's disease | |
| EP4061396A1 (en) | Treating alzheimer's disease | |
| EA202092366A1 (ru) | Применение происходящих из pedf коротких пептидов при лечении остеоартрита |